Researchers in Iran sought to quantify headaches related to personal protective equipment (PPE) among frontline health care workers.
Headaches resulting from personal protective equipment (PPE) are common and can decrease hospital staff efficiency and performance, according to results of a cross-sectional study carried out in Iran. Findings, published in Brain and Behavior, underscore the importance of considering this issue for health care personnel and providing modalities to reduce the risk of headache, researchers wrote.
Throughout the COVID-19 pandemic, frontline health workers experienced drastic changes in their daily lives, including “wearing specialized masks and clothing, extended hours of stressful work in the hospital, separation from family, along with the fear of contracting the disease and transmitting it to relatives, and the risk of death," authors explained.
As the World Health Organization recommended use of masks for medical staff operating in normal wards and masks, gowns, and shields for those in COVID-19 wards, reports of associated headache complaints among workers increased.
PPE-associated headaches could be caused by hypoxia, hypercapnia, local compression on the face or scalp, or other factors; previous studies have found that 30% to 80% of personnel who wear N95 masks report headaches, authors said.
To better evaluate the occurrence of PPE-associated headache among health care staff during the COVID-19 pandemic, investigators conducted a cross-sectional study among personnel at 4 centers in Tehran, Iran.
All centers received patients with COVID-19, and physicians, nurses, and other staff members took part in the study between April and July 2020. “Hospital staff were required to wear surgical masks in general wards and N95 masks with or without gowns, shields, and goggles in the COVID-19 wards,” the authors wrote. All participants had continuously used PPE for at least 4 hours.
In addition to completing questionnaires, participants also had their blood oxygen saturation and heart rate recorded via pulse oximeter before and 4 hours post PPE use, or if they reported shortness of breath or headache.
A total of 243 frontline health workers were included in the study; they had a mean (SD) age of 36 (8) years, and 75% of workers were women.
Analyses revealed:
Of those who developed a PPE-associated headache, 44.3% had a previous history of headache, including migraine and tension type. However, this factor was not associated with PPE-related headache. In comparison, 56% of participants “did not report a history of headaches and were considered to have developed de novo PPE-associated headaches,” researchers said.
PPE-associated headache could be due to local compression on pain-sensitive structures, worsening of pre-existing headaches, or physiological changes in heart rate or respiratory rate, in addition to anxiety about wearing the device, they hypothesized.
“Designing new breathing devices that eliminate the risk factors of headache can improve mask tolerance, which can improve PPE compliance and performance among healthcare workers,” authors concluded.
Reference
Jafari E, Togha M, Kazemizadeh H, et al. Evaluation of headache associated with personal protective equipment during COVID-19. Brain Behav. Published online November 13, 2021. doi:10.1002/brb3.2435
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen